Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
A commentary in response to the recent Cochrane review of clinical trial data on different anti-amyloid treatments, that states these medicines show ‘no clinically meaningful benefit’ for people with Alzheimer’s.
On 15 April, at the ADI Conference in Lyon, France, ADI shared the Alzheimer’s Disease Atlas, a first-of-its-kind website mapping the global landscape of Alzheimer’s disease.
As part of ADI's ongoing regional commitment to dementia policy, Diego Aguilar, Regional Director for the Americas, completed a high-impact country visit to Mexico that combined academic engagement, civil society coordination, and high-level government and industry dialogue.
This announcement reverses an earlier recommendation made by the EMA regarding donanemab as a treatment for the treatment of early symptomatic Alzheimer's disease in adults.
The National Institute for Health and Care Excellence (NICE) has concluded that the benefits from two treatments for early Alzheimer's Disease, donanemab and lecanemab, remain too small to justify the additional cost. Consequently, free access to these Alzheimer's treatments will not be provided in the UK.
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
Marketing authorisation has been granted for donanemab (Kisunla) in Australia, following announcements from Brazil, and Mexico, for the treatment of Alzheimer's disease. The authorisations in Brazil and Mexico were granted in April 2025, with the announcement of the Australian approval on 21 May 2025.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
This comes as the Appeals board of the European Commission were unable to reach a verdict following the “no opinion” decision of the Standing Committee on Medicinal Products for Human Use and the European Commission. The matter will now be referred the European Commission for a final decision.
In March 2025, ADI was involved in a range of engagements across the Latin American region, from high level symposiums in Curaçao and Mexico, to providing strategic input on draft bills in Argentina and the international bloc of Latin American countries MERCOSUR.